Cargando…

Assessment of Patients' Views on Drug Benefits and Risks: An Interview Study with Cardiovascular Patients

Better and balanced information strategies supporting cardiovascular patients' adherence are required. Cardiovascular drugs have outstanding morbidity and mortality benefits. This can be counteracted by patients' perceptions of risks. Drug information should help the patient but not fuel u...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakob, Ines, Wintsche, Ina, Frisch, Annett, Remane, Yvonne, Laufs, Ulrich, Bertsche, Thilo, Schiek, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678459/
https://www.ncbi.nlm.nih.gov/pubmed/36474547
http://dx.doi.org/10.1155/2022/6585271
_version_ 1784833989527207936
author Wakob, Ines
Wintsche, Ina
Frisch, Annett
Remane, Yvonne
Laufs, Ulrich
Bertsche, Thilo
Schiek, Susanne
author_facet Wakob, Ines
Wintsche, Ina
Frisch, Annett
Remane, Yvonne
Laufs, Ulrich
Bertsche, Thilo
Schiek, Susanne
author_sort Wakob, Ines
collection PubMed
description Better and balanced information strategies supporting cardiovascular patients' adherence are required. Cardiovascular drugs have outstanding morbidity and mortality benefits. This can be counteracted by patients' perceptions of risks. Drug information should help the patient but not fuel unwarranted fears. We performed a cross-sectional survey of patients admitted to a cardiology ward. We evaluated (i) the patients' general benefit-risk estimation of their pharmacotherapy; (ii) views on benefits; (iii) views on risks; and (iv) information sources. Additionally, we assessed aspects of anxiety and depression with the Patient Health Questionnaire-4 (PHQ-4). (i) 67 patients (66%) rated expected drug benefits higher than potential risks. (ii) 72% of benefits motivated the patients to take their medication as prescribed. Patients more frequently mentioned surrogate markers as benefits than clinical benefits (p < 0.001). (iii) 56% of risks mentioned were perceived as bothersome and 35% as concerning. Risks were more often perceived as bothersome and concerning by patients with higher PHQ-4 scores (p=0.016). (iv) Physicians were the most frequent information source of benefits (92% of patients) and risks (45%), and pharmacy staff for 27% and 14%, respectively. Laymen or media served as sources of information on benefits in 39%, for risks in 40%, and package leaflets in 26% and 36%. 42% of the patients would like to receive more information on benefits versus 27% on risks. Our results suggest that knowledge of benefits motivates patients to take their drugs as prescribed. There is already good information on surrogate markers for process control with active patient involvement. However, a lack of knowledge still exists in relation to clinical benefits. Regarding risks, it has been shown that patients with higher PHQ-4 scores are more likely to be bothered or concerned. Both emphases on clinical benefits and individualization depending on PHQ-4 scores may be valuable resources for patient counseling to support adherence.
format Online
Article
Text
id pubmed-9678459
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-96784592022-12-05 Assessment of Patients' Views on Drug Benefits and Risks: An Interview Study with Cardiovascular Patients Wakob, Ines Wintsche, Ina Frisch, Annett Remane, Yvonne Laufs, Ulrich Bertsche, Thilo Schiek, Susanne Int J Clin Pract Research Article Better and balanced information strategies supporting cardiovascular patients' adherence are required. Cardiovascular drugs have outstanding morbidity and mortality benefits. This can be counteracted by patients' perceptions of risks. Drug information should help the patient but not fuel unwarranted fears. We performed a cross-sectional survey of patients admitted to a cardiology ward. We evaluated (i) the patients' general benefit-risk estimation of their pharmacotherapy; (ii) views on benefits; (iii) views on risks; and (iv) information sources. Additionally, we assessed aspects of anxiety and depression with the Patient Health Questionnaire-4 (PHQ-4). (i) 67 patients (66%) rated expected drug benefits higher than potential risks. (ii) 72% of benefits motivated the patients to take their medication as prescribed. Patients more frequently mentioned surrogate markers as benefits than clinical benefits (p < 0.001). (iii) 56% of risks mentioned were perceived as bothersome and 35% as concerning. Risks were more often perceived as bothersome and concerning by patients with higher PHQ-4 scores (p=0.016). (iv) Physicians were the most frequent information source of benefits (92% of patients) and risks (45%), and pharmacy staff for 27% and 14%, respectively. Laymen or media served as sources of information on benefits in 39%, for risks in 40%, and package leaflets in 26% and 36%. 42% of the patients would like to receive more information on benefits versus 27% on risks. Our results suggest that knowledge of benefits motivates patients to take their drugs as prescribed. There is already good information on surrogate markers for process control with active patient involvement. However, a lack of knowledge still exists in relation to clinical benefits. Regarding risks, it has been shown that patients with higher PHQ-4 scores are more likely to be bothered or concerned. Both emphases on clinical benefits and individualization depending on PHQ-4 scores may be valuable resources for patient counseling to support adherence. Hindawi 2022-11-14 /pmc/articles/PMC9678459/ /pubmed/36474547 http://dx.doi.org/10.1155/2022/6585271 Text en Copyright © 2022 Ines Wakob et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wakob, Ines
Wintsche, Ina
Frisch, Annett
Remane, Yvonne
Laufs, Ulrich
Bertsche, Thilo
Schiek, Susanne
Assessment of Patients' Views on Drug Benefits and Risks: An Interview Study with Cardiovascular Patients
title Assessment of Patients' Views on Drug Benefits and Risks: An Interview Study with Cardiovascular Patients
title_full Assessment of Patients' Views on Drug Benefits and Risks: An Interview Study with Cardiovascular Patients
title_fullStr Assessment of Patients' Views on Drug Benefits and Risks: An Interview Study with Cardiovascular Patients
title_full_unstemmed Assessment of Patients' Views on Drug Benefits and Risks: An Interview Study with Cardiovascular Patients
title_short Assessment of Patients' Views on Drug Benefits and Risks: An Interview Study with Cardiovascular Patients
title_sort assessment of patients' views on drug benefits and risks: an interview study with cardiovascular patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678459/
https://www.ncbi.nlm.nih.gov/pubmed/36474547
http://dx.doi.org/10.1155/2022/6585271
work_keys_str_mv AT wakobines assessmentofpatientsviewsondrugbenefitsandrisksaninterviewstudywithcardiovascularpatients
AT wintscheina assessmentofpatientsviewsondrugbenefitsandrisksaninterviewstudywithcardiovascularpatients
AT frischannett assessmentofpatientsviewsondrugbenefitsandrisksaninterviewstudywithcardiovascularpatients
AT remaneyvonne assessmentofpatientsviewsondrugbenefitsandrisksaninterviewstudywithcardiovascularpatients
AT laufsulrich assessmentofpatientsviewsondrugbenefitsandrisksaninterviewstudywithcardiovascularpatients
AT bertschethilo assessmentofpatientsviewsondrugbenefitsandrisksaninterviewstudywithcardiovascularpatients
AT schieksusanne assessmentofpatientsviewsondrugbenefitsandrisksaninterviewstudywithcardiovascularpatients